Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways

Cancer Res. 2000 Aug 1;60(15):4277-83.

Abstract

We have shown recently that the multifunctional growth factor, scatter factor/hepatocyte growth factor (SF/HGF), and its receptor c-met enhance the malignancy of human glioblastoma through an autocrine stimulatory loop (R. Abounader et al., J. Natl. Cancer Inst., 91: 1548-1556, 1999). This report examines the effects of SF/HGF:c-met signaling on human glioma cell responses to DNA-damaging agents. Pretreating U373 human glioblastoma cells with recombinant SF/HGF partially abrogated their cytotoxic responses to gamma irradiation, cisplatin, camptothecin, Adriamycin, and Taxol in vitro. This cytoprotective effect of SF/HGF occurred at least in part through an inhibition of apoptosis, as evidenced by diminished terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling index and reduced DNA laddering. Anti-c-met U1/ribozyme gene transfer inhibited the ability of SF/HGF to protect against single-strand DNA breakage, DNA fragmentation, and glioblastoma cell death caused by DNA-damaging agents, demonstrating a requirement for c-met receptor function. Phosphorylation of the cell survival-promoting kinase Akt (protein kinase B) resulted from SF/HGF treatment of U373 cells, and both Akt phosphorylation and cell survival induced by SF/HGF were inhibited by phosphatidylinositol 3-kinase inhibitors but not by inhibitors of mitogen-activated protein kinase kinase or protein kinase C. Cytoprotection by SF/HGF in vitro was also inhibited by transient expression of dominant-negative Akt. Transgenic SF/HGF expression by intracranial 9L gliosarcomas reduced tumor cell sensitivity to gamma irradiation, confirming the cytoprotective effect of SF/HGF in vivo. These findings demonstrate that c-met receptor activation by SF/HGF protects certain glioblastoma cells from DNA-damaging agents by activating phosphoinositol 3-kinase-dependent and Akt-dependent antiapoptotic pathways.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Gene Expression
  • Gene Transfer Techniques
  • Glioblastoma / enzymology
  • Glioblastoma / pathology*
  • Gliosarcoma / enzymology
  • Gliosarcoma / pathology
  • Hepatocyte Growth Factor / pharmacology*
  • Hepatocyte Growth Factor / physiology
  • Humans
  • Male
  • Phosphatidylinositol 3-Kinases / physiology*
  • Protein Serine-Threonine Kinases*
  • Protein-Tyrosine Kinases / physiology
  • Proto-Oncogene Proteins / physiology*
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors
  • Proto-Oncogene Proteins c-met / genetics
  • Proto-Oncogene Proteins c-met / physiology
  • RNA, Catalytic / genetics
  • Rats
  • Rats, Inbred F344
  • Recombinant Proteins / pharmacology
  • Ribonucleoprotein, U1 Small Nuclear / genetics
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Tumor Cells, Cultured

Substances

  • Proto-Oncogene Proteins
  • RNA, Catalytic
  • Recombinant Proteins
  • Ribonucleoprotein, U1 Small Nuclear
  • Hepatocyte Growth Factor
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-met
  • AKT1 protein, human
  • Akt1 protein, rat
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt